A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Open accessPublished version of a preprint
Abstract
Abstract Background Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy. Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC. In this study, we performed a comprehensive portrait of immunologic landscape of TNBC based on 2 large-scale breast cancer genomic data. Methods We compared expression levels of immune-related genes and gene-sets among TNBC, non-TNBC, and normal tissue, and within TNBCs of different genotypic or phenotypic features. Moreover, we explored the association of immune-related genes or gene-sets expression and survival prognosis in TNBC patients. Results We found that almost all analyzed immune-related gene-sets had significantly higher expression levels in TNBC than non-TNBC. These highly expressed gene-sets in TNBC included 15 immune cell type and function, human leukocyte antigen (HLA), cancer testis (CT), tumor-infiltrating lymphocytes (TILs), immune cell infiltrate, regulatory T (Treg) cells, immune checkpoint, cytokine and cytokine receptor, metastasis-promoting, pro-inflammatory and parainflammation (PI) gene-sets. Moreover, TP53-mutated , TNBC had significantly higher expression levels of the immune checkpoint, Treg, PI, and CT gene-sets, and lower expression levels of the immune cell infiltrate gene-set than TP53 -wildtype TNBC. Furthermore, we found that elevated expression of most of the immune-related genes in TNBC was associated with the ER-status, while some were associated with both ER-and HER2-status. Elevated expression of the immune-related genes in TNBC was also associated with the high tumor mutation burden (TMB) in TNBC. Finally, elevated expression of the immune-related gene-sets was likely to be associated with better survival prognosis in TNBC. Conclusions Our findings suggest that TNBC is a breast cancer subtype with particularly strong immunogenicity, and therefore could be propitious to immunotherapeutic options.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Despite strong immunogenicity and a higher prevalence of tumor-infiltrating lymphocytes in TNBC, patients often progress to metastasis with poor clinical outcomes.
“Paradoxically, despite strong immunogenicity and a higher prevalence of tumor-infiltrating lymphocytes (TILs) in TNBC3, patients often progress to metastasis with poor clinical outcomes1.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712 · see citing works
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 12,116 · see citing works
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · see citing works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · see citing works
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,390 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · see citing works
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,761 · see citing works
Pereira, B., Chin, S., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L. R., Russell, R., Sammut, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,712 · see citing works
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,433 · see citing works
Adams, S., Gray, R. J., Demaria, S., Goldstein, L. J., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,301 · see citing works
ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients
Kim, S. (2015) · Communications for Statistical Applications and Methods · doi:10.5351/csam.2015.22.6.665 · Cited by 1,106 · see citing works
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · see citing works
Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovář, M., Rubinstein, M., Surh, C., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 940 · see citing works
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 931 · see citing works
Cytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 906 · see citing works
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695 · see citing works
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687 · see citing works
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601 · see citing works
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554 · see citing works
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
de Almeida, L. G. P., Sakabe, N. J., deOliveira, A. R., da Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y., Chua, R., Gurung, S., Gnjatic, S., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 436 · see citing works
Hartman, Z. C., Poage, G. M., den Hollander, P., Tsimelzon, A. I., Hill, J. L., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Mills, G. B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4524-t · Cited by 408 · see citing works
The p53 pathway in breast cancer
Gasco, M., Shami, S. K., & Crook, T. (2002) · Breast Cancer Research · doi:10.1186/bcr426 · Cited by 393 · see citing works
Understanding and treating triple-negative breast cancer
Carey, L., & Anders, C. (2021) · PubMed · doi:10.17615/85ph-f542 · Cited by 352 · see citing works
New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Mayer, I. A., Abramson, V. G., Lehmann, B. D., & Pietenpol, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0583 · Cited by 320 · see citing works
The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3
Kane, L., & Weiss, A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00008.x · Cited by 260 · see citing works
Genome-wide in vivo screen identifies novel host regulators of metastatic colonization
Sanger Mouse Genetics Project, van der Weyden, L., Arends, M. J., Campbell, A. D., Bald, T., Wardle‐Jones, H., Griggs, N., Velasco‐Herrera, M. D. C., Tüting, T., Sansom, O. J., et al. (2017) · Nature · doi:10.1038/nature20792 · Cited by 219 · see citing works
Svoronos, N., Perales‐Puchalt, A., Allegrezza, M. J., Rutkowski, M. R., Payne, K. K., Tesone, A. J., Nguyen, J. M., Curiel, T. J., Cadungog, M. G., Singhal, S. K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0502 · Cited by 218 · see citing works
Emens, L. A., Braiteh, F. S., Cassier, P. A., Delord, J., Eder, J. P., Fassò, M., Xiao, Y., Wang, Y., Molinero, L. L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211 · see citing works
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Allen, E. M. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 177 · see citing works
Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · see citing works
Traina, T. A., Miller, K. D., Yardley, D. A., O’Shaughnessy, J., Cortés, J., Awada, A. H., Kelly, C. M., Trudeau, M., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164 · see citing works
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Safonov, A. M., Jiang, T., Bianchini, G., Győrffy, B., Karn, T., Hatzis, C., & Pusztai, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3478 · Cited by 150 · see citing works
Molecularly targeted therapies for metastatic triple-negative breast cancer
Bayraktar, S., & Glück, S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2421-5 · Cited by 146 · see citing works
Hix, L. M., Karavitis, J., Khan, M. W., Shi, Y. H., Khazaie, K., & Zhang, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441402 · Cited by 134 · see citing works
Bertucci, F., Ueno, N. T., Finetti, P., Vermeulen, P. B., Lucci, A., Robertson, F. M., Marsan, M., Iwamoto, T., Krishnamurthy, S., Masuda, H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt496 · Cited by 117 · see citing works
Wheler, J. J., Jankú, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0196 · Cited by 106 · see citing works
Widespread parainflammation in human cancer
Aran, D., Lasry, A., Zinger, A., Biton, M., Pikarsky, E., Hellman, A., Butte, A. J., & Ben‐Neriah, Y. (2016) · Genome biology · doi:10.1186/s13059-016-0995-z · Cited by 104 · see citing works
Prognostic and predictive immune gene signatures in breast cancer
Bedognetti, D., Hendrickx, W., Marincola, F. M., & Miller, L. D. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000234 · Cited by 103 · see citing works
Renaud, S., Pugacheva, E. M., Delgado, M. D., Braunschweig, R., Abdullaev, Z., Loukinov, D. I., Benhattar, J., & Lobanenkov, V. V. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm896 · Cited by 99 · see citing works
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Miller, L. D., Chou, J., Black, M. A., Print, C. G., Chifman, J., Alistar, A. T., Putti, T. C., Zhou, X., Bedognetti, D., Hendrickx, W., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0149 · Cited by 99 · see citing works
Jansson, T. E., Inganäs, M., Sjögren, S., Norberg, T., Lindgren, A., Holmberg, L., & Bergh, J. C. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2745 · Cited by 86 · see citing works
Krishnamurti, U., Wetherilt, C. S., Yang, J. L., Peng, L., & Li, X. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.01.004 · Cited by 80 · see citing works
Lee, H. J., Lee, J.-J., Song, I. H., Park, I. A., Kang, J. K., Yu, J. H., Ahn, J., & Gong, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3438-8 · Cited by 71 · see citing works
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
Massink, M. P. G., Kooi, I. E., Martens, J. W. M., Waisfisz, Q., & Meijers-Heijboer, H. E. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1880-y · Cited by 59 · see citing works
Personal neoantigen cancer vaccines
Fritsch, E. F., Hacohen, N., & Wu, C. J. (2014) · OncoImmunology · doi:10.4161/onci.29311 · Cited by 56 · see citing works
Bonsang‐Kitzis, H., Sadacca, B., Hamy, A., Moarii, M., Pinheiro, A., Laurent, C., & Reyal, F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1061176 · Cited by 40 · see citing works
Iakovleva, N. V., Gorbushin, A. M., & Storey, K. B. (2006) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2005.12.008 · Cited by 37 · see citing works
Characterization of cytokinome landscape for clinical responses in human cancers
Wong, H. S.-C., Chang, C., Liu, X., Huang, W., & Chang, W. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214789 · Cited by 31 · see citing works
Martínez‐Canales, S., Cifuentes, F. T., de Rodas, M. L., Serrano‐Oviedo, L., Galán‐Moya, E. M., Amir, E., Pandiella, A., Győrffy, B., & Ocaña, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175128 · Cited by 30 · see citing works
Wang, X., & Guda, C. (2016) · Medicine · doi:10.1097/md.0000000000004321 · Cited by 29 · see citing works
Self-citationBardia, A., Diamond, J. R., Messersmith, W. A., Mayer, I. A., Isakoff, S. J., Abramson, V. G., Berlin, J. D., Starodub, A., O’Shaughnessy, J., Kalinsky, K. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba509 · Cited by 4 · see citing works
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Classification of triple-negative breast cancers based on Immunogenomic profiling
He, Y., Jiang, Z., Chen, C., & Wang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1002-1 · Cited by 626 · see citing works
Self-citationTriple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Salcedo, J. M. M., Oza, G., Sharma, A. K., Arriaga, L., Hernández, J. M. H., Rotello, V. M., & Tapia-Ramı́rez, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 337 · see citing works
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes
Onkar, S., Carleton, N. M., Lucas, P. C., Bruno, T. C., Lee, A. V., Vignali, D. A. A., & Oesterreich, S. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0475 · Cited by 219 · see citing works
Liu, Q., Zhang, J., Guo, C., Wang, M., Wang, C., Yan, Y., Sun, L., Wang, D., Zhang, L., Yu, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.004 · Cited by 219 · see citing works
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200 · see citing works
Self-citationCorrelate tumor mutation burden with immune signatures in human cancers
Wang, X., & Li, M. (2019) · BMC Immunology · doi:10.1186/s12865-018-0285-5 · Cited by 188 · see citing works
Self-citationJu, M., Bi, J., Wei, Q., Jiang, L., Guan, Q., Zhang, M., Song, X., Chen, T., Fan, J., Li, X., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa345 · Cited by 183 · see citing works
Hubert, P., Roncarati, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001966 · Cited by 186 · see citing works
Xu, X., Zhang, L., He, X., Zhang, P., Sun, C., Xu, X., Lu, Y., & Li, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.139 · Cited by 176 · see citing works
The Immunology of Hormone Receptor Positive Breast Cancer
Goldberg, J., Pastorello, R., Vallius, T., Davis, J. A., Cui, Y. X., Agudo, J., Waks, A. G., Keenan, T. E., McAllister, S. S., Tolaney, S. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674192 · Cited by 175 · see citing works
Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.068 · Cited by 170 · see citing works
Self-citationNotch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
Giuli, M. V., Giuliani, E., Screpanti, I., Bellavia, D., & Checquolo, S. (2019) · Journal of Oncology · doi:10.1155/2019/8707053 · Cited by 163 · see citing works
Kong, X., Qi, Y., Wang, X., Jiang, R., Wang, J., Fang, Y., Gao, J., & Hwang, K. C. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101070 · Cited by 163 · see citing works
Self-citationLyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.07.009 · Cited by 134 · see citing works
Self-citationImmunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Abdou, Y. G., Goudarzi, A., Yu, J. X., Upadhaya, S., Vincent, B. G., & Carey, L. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00486-y · Cited by 134 · see citing works
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 133 · see citing works
Photo-activated chemo-immunotherapy for metastatic cancer using a synergistic graphene nanosystem
Zhou, F., Wang, M., Luo, T., Qu, J., & Chen, W. R. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120421 · Cited by 124 · see citing works
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
Kúdelová, E., Smolár, M., Holubeková, V., Horňáková, A., Dvorská, D., Lučanský, V., Koklesová, L., Kúdela, E., & Kubatka, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314937 · Cited by 122 · see citing works
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 113 · see citing works
Self-citationTang, B., Zhu, J., Zhao, Z., Lu, C., Liu, S., Fang, S., Zheng, L., Zhang, N., Chen, M., Xu, M., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.01.018 · Cited by 110 · see citing works
Atezolizumab for the treatment of triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552255 · Cited by 109 · see citing works
Singh, S., Kumar, S., Srivastava, R. K., Nandi, A., Thacker, G., Murali, H., Kim, S., Baldeon, M. A., Tobias, J. W., Blanco, M. A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0495-y · Cited by 107 · see citing works
An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles
Li, M., Zhang, Z., Li, L., & Wang, X. (2020) · Communications Biology · doi:10.1038/s42003-020-01230-7 · Cited by 101 · see citing works
Self-citationZhao, P., Xu, Y., Ji, W., Zhou, S., Li, L., Qiu, L., Qian, Z., Wang, X., & Zhang, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00932-2 · Cited by 98 · see citing works
Self-citationHow I treat metastatic triple-negative breast cancer
Caparica, R., Lambertini, M., & de Azambuja, E. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000504 · Cited by 97 · see citing works
Tan, A. H. Y., Tu, W., McCuaig, R., Hardy, K., Donovan, T., Tsimbalyuk, S., Forwood, J. K., & Rao, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01351 · Cited by 94 · see citing works
TP53 Mutations Promote Immunogenic Activity in Breast Cancer
Liu, Z., Jiang, Z., Gao, Y., Wang, L., Chen, C., & Wang, X. (2018) · Journal of Oncology · doi:10.1155/2019/5952836 · Cited by 90 · see citing works
Self-citationAnalyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02491-w · Cited by 89 · see citing works
Self-citationTargeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Stamm, H., Oliveira‐Ferrer, L., Grossjohann, E.-M., Muschhammer, J., Thaden, V., Brauneck, F., Kischel, R., Müller, V., Bokemeyer, C., Fiedler, W., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1674605 · Cited by 88 · see citing works
Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Loizides, S., & Constantinidou, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1095839 · Cited by 90 · see citing works
Immature natural killer cells promote progression of triple-negative breast cancer
Thacker, G., Henry, S., Nandi, A., Debnath, R., Singh, S., Nayak, A., Susnik, B., Boone, M., Zhang, Q. H., Kesmodel, S. B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4414 · Cited by 85 · see citing works
Ribeiro, R., Carvalho, M. J., Gonçalves, J., & Moreira, J. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903065 · Cited by 84 · see citing works
A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse
Hong, H.-C., Chuang, C., Huang, W., Weng, S., Chen, C., Chang, K.-H., Liao, K., & Huang, H. (2020) · Theranostics · doi:10.7150/thno.46142 · Cited by 79 · see citing works
Naik, A., & Decock, J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.598626 · Cited by 76 · see citing works
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 70 · see citing works
Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology
Valdés‐Mora, F., Handler, K., Law, A. M. K., Salomon, R., Oakes, S. R., Ormandy, C. J., & Gallego‐Ortega, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02582 · Cited by 68 · see citing works
Identification of gastric cancer subtypes based on pathway clustering
Li, L., & Wang, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00186-z · Cited by 62 · see citing works
Self-citationPRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
Al‐Khadairi, G., Naik, A., Thomas, R., AlSulaiti, B., Rizly, S., & Decock, J. V. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-018-1757-3 · Cited by 62 · see citing works
Immune response and inflammation in cancer health disparities
Bailey‐Whyte, M., Lord, B., & Ambs, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.010 · Cited by 61 · see citing works
Wang, H., Milberg, O., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L. K., Santa-Maria, C. A., & Popel, A. S. (2019) · Royal Society Open Science · doi:10.1098/rsos.190366 · Cited by 60 · see citing works
Boivin, G., Kalambaden, P., Faget, J., Rusakiewicz, S., Montay‐Gruel, P., Meylan, E., Bourhis, J., Lesec, G., & Vozenin, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00256 · Cited by 59 · see citing works
Jiang, Y., & Fan, L. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112851 · Cited by 56 · see citing works
Tian, T., Zhao, Y., Zheng, J., Jin, S., Liu, Z., & Wang, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.017 · Cited by 53 · see citing works
Self-citationLi, L., Liang, X., He, T., Li, X., Huang, X., Wang, N., Shen, M., Shu, Y., Wu, R., Zhang, M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121815 · Cited by 53 · see citing works
Zeindler, J., Soysal, S. D., Piscuoglio, S., Ng, C. K. Y., Mechera, R., Isaak, A., Weber, W. P., Muenst, S. E., & Kurzeder, C. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00200 · Cited by 53 · see citing works
Cancer subtype classification and modeling by pathway attention and propagation
Lee, S., Lim, S., Lee, T., Sung, I., & Kim, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa203 · Cited by 53 · see citing works
PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 52 · see citing works
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
Sadeghalvad, M., Mohammadi‐Motlagh, H., & Rezaei, N. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05954-2 · Cited by 52 · see citing works
Peng, Z., Su, P., Yang, Y., Yao, X., Zhang, Y., Jin, F., & Yang, B. (2020) · Journal of Cancer · doi:10.7150/jca.46301 · Cited by 50 · see citing works
Velloso, F. J., Campos, A. R., Sogayar, M. C., & Correa, R. G. (2019) · BMC Genomics · doi:10.1186/s12864-019-5523-6 · Cited by 48 · see citing works
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Valencia, G., Rioja, P., Morante, Z., Ruiz, R., Fuentes, H. A., Castañeda, C. A., Vidaurre, T., Neciosup, S. P., & Gómez, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i3.219 · Cited by 46 · see citing works
Romero-Cordoba, S. L., Meneghini, E., Sant, M., Iorio, M. V., Sfondrini, L., Paolini, B., Agresti, R., Tagliabue, E., & Bianchi, F. (2019) · Cancers · doi:10.3390/cancers11070911 · Cited by 47 · see citing works
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 47 · see citing works
Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer
Hodge, J., Wang, F., Wang, J., Liu, Q., Saaoud, F., Wang, Y., Singh, U. P., Chen, H., Luo, M., Ai, W., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1724761 · Cited by 46 · see citing works
Roelands, J. P., Mall, R., Almeer, H., Thomas, R., Mohamed, M. G., Bedri, S. A., Al‐Bader, S. B., Junejo, K., Ziv, E., Sayaman, R. W., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00215-x · Cited by 46 · see citing works
Zhu, B., Cai, Y., Zhou, L., Zhao, L., Chen, J., Shan, X., Sun, X., You, Q., Gong, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55904-z · Cited by 48 · see citing works
A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes
Shen, Y., Chi, H., Xu, K., Li, Y., Yin, X., Chen, S., Yang, Q., He, M., Zhu, G., & Li, X. (2022) · Brain Sciences · doi:10.3390/brainsci12060700 · Cited by 42 · see citing works
Cheng, X. M., Cao, Y., Wang, X., Cheng, L., Liu, Y., Jun, L., Peng, W., & Shi, D. (2022) · Journal of Immunology Research · doi:10.1155/2022/5254911 · Cited by 42 · see citing works
Self-citationTargeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements
Raman, R., Debata, S., Govindarajan, T., & Kumar, P. (2025) · Cancer Medicine · doi:10.1002/cam4.70803 · Cited by 41 · see citing works
Alghamdi, R. A., & Al-Zahrani, M. H. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103596 · Cited by 39 · see citing works
Schepisi, G., Gianni, C., Palleschi, M., Bleve, S., Casadei, C., Lolli, C., Ridolfi, L., Martinelli, G., & Giorgi, U. D. (2023) · Cancers · doi:10.3390/cancers15051597 · Cited by 39 · see citing works
Terkelsen, T., Russo, F., Gromov, P., Haakensen, V. D., Brunak, S., Gromova, I., Krogh, A., & Papaleo, E. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01295-6 · Cited by 37 · see citing works
DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood
Ennour‐Idrissi, K., Dragic, D., Issa, E., Michaud, A., Chang, S.-L., Provencher, L., Durocher, F., & Diorio, C. (2020) · Cancers · doi:10.3390/cancers12113088 · Cited by 35 · see citing works
Farshbafnadi, M., Khoshbin, A. P., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107876 · Cited by 36 · see citing works
Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
Naik, A., Thomas, R., Al‐Khadairi, G., Bacha, R., Hendrickx, W., & Decock, J. V. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16967 · Cited by 33 · see citing works
Jones, N., Xiu, J., Rocconi, R. P., Herzog, T. J., & Winer, I. S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.035 · Cited by 33 · see citing works
He, Z., Khatib, A., & Creemers, J. W. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.001 · Cited by 33 · see citing works
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Qureshi, S., Chan, N., George, M. A., Ganesan, S., Toppmeyer, D., & Omene, C. O. (2022) · Biomarker Insights · doi:10.1177/11772719221078774 · Cited by 35 · see citing works
Kim, H., Choi, J., & Lee, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051130 · Cited by 30 · see citing works
Takahashi‐Ruiz, L., Fermaintt, C. S., Wilkinson, N. J., Chan, P. Y. W., Mooberry, S. L., & Risinger, A. L. (2022) · Cancers · doi:10.3390/cancers14235962 · Cited by 30 · see citing works
Immunological classification of gliomas based on immunogenomic profiling
Feng, Q., Li, L., Li, M., & Wang, X. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02030-w · Cited by 29 · see citing works
Self-citationImmunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 28 · see citing works
Toney, N. J., Opdenaker, L. M., Cicek, K., Frerichs, L., Kennington, C. R., Oberly, S., Archinal, H., Somasundaram, R., & Sims‐Mourtada, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03319-5 · Cited by 27 · see citing works
Wang, J., Akter, R., Shahriar, M. F., & Uddin, M. N. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610350 · Cited by 27 · see citing works
Soliman, R. A., Youness, R. A., Manie, T., Khallaf, E., El‐Shazly, M., AbdelMohsen, M. M., Handoussa, H., & Gad, M. Z. (2021) · Biocell · doi:10.32604/biocell.2022.016636 · Cited by 26 · see citing works
Chen, Y., You, S., Li, J., Zhang, Y., Kokaraki, G., Epstein, E., Carlson, J. W., Huang, W., & Haglund, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788959 · Cited by 26 · see citing works
DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy
Li, L., Chen, C., & Wang, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab202 · Cited by 25 · see citing works
Self-citationJu, M., Jiang, L., Wei, Q., Yu, L., Chen, L., Wang, Y., Hu, B., Qian, P., Zhang, M., Zhou, C., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s326784 · Cited by 25 · see citing works
Boissière‐Michot, F., Chateau, M., Thézenas, S., Guiu, S., Bobrie, A., & Jacot, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058424 · Cited by 25 · see citing works
Kagihara, J. A., Andress, M., & Diamond, J. R. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1730694 · Cited by 26 · see citing works
Ghebeh, H., Alsayed, A., Eiada, R., Cabangon, L., Ajarim, D. S., Suleman, K., Tulbah, A. M., & Al‐Tweigeri, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-98113-6 · Cited by 24 · see citing works
Mangia, A., Saponaro, C., Vagheggini, A., Opinto, G., Centonze, M., Vicenti, C., Popescu, O., Pastena, M. I., Giotta, F., & Silvestris, N. (2019) · Cancers · doi:10.3390/cancers11091393 · Cited by 24 · see citing works
Fabbri, F., Salvi, S., & Bravaccini, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.015 · Cited by 24 · see citing works
Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
Zhao, Z., Zhao, D., Ji, X., Wang, Y., & Wang, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00691 · Cited by 24 · see citing works
Zhao, N., Zhu, W., Wang, J., Liu, W., Kang, L., Yu, R., & Liu, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107924 · Cited by 23 · see citing works
Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
Liu, Q., Nie, R., Li, M., Li, L., Zhou, H., Lu, H. J., & Wang, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.005 · Cited by 23 · see citing works
Self-citationUchimiak, K., Badowska-Kozakiewicz, A. M., Sobiborowicz, A., & Deptała, A. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221099869 · Cited by 23 · see citing works
LAG-3 expression in tumor microenvironment of triple-negative breast cancer
Tahtacı, G., Günel, N., Sadioğlu, A., Akyürek, N., Boz, O., & ÜNER, A. (2023) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5567 · Cited by 23 · see citing works
Simmons, C. E., Brezden‐Masley, C., McCarthy, J. S., McLeod, D., & Joy, A. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920909091 · Cited by 23 · see citing works
Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy
Niture, S. K., Ghosh, S., Jaboin, J. J., & Seneviratne, D. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062795 · Cited by 22 · see citing works
Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma
Zhang, C., Dang, D., Liu, C., Wang, Y., & Cong, X. (2021) · Journal of Cancer · doi:10.7150/jca.53697 · Cited by 22 · see citing works
Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
Huertas-Caro, C. A., Ramirez, M. A., González-Torres, H. J., Sanabria‐Salas, M. C., & Serrano-Gomez, S. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910976 · Cited by 22 · see citing works
Jiang, Q., Xie, M., Chen, R., Yan, F., Ye, C., Li, Q., Xu, S., Wu, W., Jia, Y., Shen, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973601 · Cited by 22 · see citing works
Yu, J., Zhikun, G., & Wang, L. (2023) · Life · doi:10.3390/life13051189 · Cited by 21 · see citing works
LeVee, A. A., Wong, M. H., Flores, S., Ruel, N. H., McArthur, H. L., Waisman, J. R., & Mortimer, J. E. (2024) · The Oncologist · doi:10.1093/oncolo/oyae064 · Cited by 22 · see citing works
Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
Tan, R., Li, H., Huang, Z., Zhou, Y., Tao, M., Gao, X., & Xu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-60030-5 · Cited by 21 · see citing works
Li, S., Gao, J., Xu, Q., Zhang, X., Huang, M., Dai, X., Huang, K., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693314 · Cited by 21 · see citing works
Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
Zhou, X., Qiu, S., Nie, L., Jin, D., Jin, K., Zheng, X., Yang, L., & Wei, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01429 · Cited by 20 · see citing works
Jørgensen, N., Hviid, T. V. F., Nielsen, L. B., Sønderstrup, I. M. H., Eriksen, J. O., Ejlertsen, B., Gerdes, A., Kruse, T. A., Thomassen, M., Jensen, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01514-7 · Cited by 20 · see citing works
Paranthaman, P., & Veerappapillai, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-01970-6 · Cited by 20 · see citing works
- Authors
- Liu, Z., Li, M., Jiang, Z., & Wang, X.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Wang, Xiaosheng
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 11
- Issue
- 2
- Pages
- 311-329
- ISSN
- 1936-5233 (ISSN-L)
- PMC
- PMC5884188
- OpenAlex
- W2766581433
- Cited by
- 275
- References
- 69
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 22 · 2023: 39 · 2022: 45 · 2021: 51 · 2020: 46 · 2019: 24 · 2018: 9
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Translational Oncology (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- China Pharmaceutical University (2632018YX01, 3150120001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- triple-negative breast cancer, tumor immunogenicity, immune pathways, immunotherapy, breast cancer subtypes, survival prediction, genomic data analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
